For those who thought that the pharma/biotech sector is in for an extraordinary run after Donald Trump's unexpected victory, his latest vow to crack down on excessive drug price hikes comes as a bolt from the blue.
Pfizer (PFE) fined for hiking price of an anti-epilepsy drug by up to 2,600% by the Competition and Markets Authority of the UK.
Mylan (MYL) has revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on integrating acquisitions.
It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.
Shares of the iShares Nasdaq Biotechnology ETF (IBB) are down more than 3.6% in morning trading Wednesday following a new warning from President-elect Donald Trump that he will indeed be targeting high drug prices.
Shares of Teva Pharmaceutical Industries (TEVA) slipped over 5.8% in morning trading Tuesday after the company announced a change in upper-level management.
Mylan CEO Heather Bresch arrived at the 2016 Forbes Healthcare Summit on December 1 surrounded by a cloud of fresh controversy, this one created by her mere appearance at the event. Bresch had refused to testify at a Congressional hearing the day before, where Senator Chuck Grassley (R-Iowa) had planned [...]
The CEO of Mylan, the maker of the life-saving EpiPen device said she hopes the pricing controversy over the life-saving device for allergy sufferers leads to changes in how drugs are priced in the U.S.
(Reuters) - Mylan NV has declined a U.S. Senate committee request to testify about a $465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment.
This week, companies like Roche (RHHBY) presented data at the annual meeting of the American College of Rheumatology (ACR).
Here is a look at key takeaways from Teva's (TEVA) third quarter conference call.
Pharma stocks surged on Trump's win with companies like Pfizer (PFE) shooting up more than 12% over the last few days.